平成30年度

巻頭言

平成30年度
ライフサイエンス研究所紀要発刊によせて
研究所長
伊木　雅之（公衆衛生学教室教授）

　ライフサイエンス研究所は近畿大学本部直轄の組織で、医学部からは独立した研究施設ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、共同兼任の状態にあることから、医学部の研究に寄与するところが大きな施設といえるでしょう。
　私立大学医学部や私立医科大学で基礎的な研究に専念する医学部出身者は元来多くありませんでしたが、新臨床研修医制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。
私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけていると考えられます。
　しかし、時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことと考えます。基礎系および臨床系の多くの教室の多大な御尽力と、研究所の技術員の奮闘に敬意を表するとともに、引き続いてのご協力をお願いする次第です。

平成30年度ライフサイエンス研究所紀要

公衆衛生学教室（伊木　雅之　教授）

1. Tamaki J, Kouda K, Fujita Y, Iki M, Yura A, Miura M, Sato Y, Okamoto N, Kurumatani N.
   Ratio of Endogenous Secretory Receptor for Advanced Glycation End Products to Pentosidine Predicts Fractures in Men.
   J Clin Endocrinol Metab. 2018 Jan 1;103(1):85-94.

病理学教室（伊藤　彰彦　教授）

1. Progression of Pulmonary Emphysema and Continued Increase in Ectodomain Shedding of Cell Adhesion Molecule 1 After Cessation of Cigarette Smoke Exposure in Mice
2. Frontiers _ Renal ADAM10 and 17_ Their Physiological and Medical Meanings _ Cell and Developmental Biology
   

免疫学教室（宮澤　正顯　教授）

1. Meira e Cruz, M., M. Miyazawa, R. Manfredini, D. Cardinali, J. A. Madrid, R. Reiter, J. F. Araujo, R. Agostinho, D. Acuña-Castroviejo.
   Impact of daylight saving time on circadian timing system: An expert　statement. Eur. J. Intern. Med. 60: 1-3, 2019.
2. Yonesaka, K., K. Haratani, S. Takamura, H. Sakai, R. Kato, N. Takegawa, T. Takahama, K. Tanaka, H. Hayashi, M. Takeda, S. Kato, O. Maenishi, K. Sakai, Y. Chiba, T. Okabe, K. Kudo, Y. Hasegawa, H. Kaneda, M. Yamato, K. Hirotani, M. Miyazawa, K. Nishio, and K. Nakagawa.
   B7-H3 negatively modulates CTL-mediated cancer immunity. Clin. Cancer Res. 24:2653-2664, 2018.

ゲノム生物学教室（西尾　和人　教授）

1. Oiso N, Sakai K, Yanagihara S, Nishio K, Kawada A.
   Genital mucosal melanoma with somatic SF3B1 R625C mutation. Eur J Dermatol,28(3),414-415,10.1684/ejd.2018.3281. 2018 Apr
2. Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.
   A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast,40,67-75,10.1016/j.breast.2018.04.010,Epub 2018 Apr 23
3. Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K.
   HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Breast Cancer,25(5),605-613,10.1007/s12282-018-0861-9,2018 Apr
   
4. Takeda M, Sakai K, Hayashi H, Tanaka K, Tanizaki J, Takahama T, Haratani K, Nishio K, Nakagawa K.
   Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2. Oncotarget,9(30),21132-21140,10.18632/oncotarget. 24958,2018 Apr
5. Makuuchi Y, Hayashi H, Haratani K, Tanizaki J, Tanaka K, Takeda M, Sakai K, Shimizu S, Ito A, Nishio K, Nakagawa K.
   A case of ALK-rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib. Oncotarget,9(33),23315-23319,10.18632/oncotarget.25143,2018 May
6. Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F.
   Heterogeneity of EGFR-mutant clones and PD-L1 highly-expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor. Ann Oncol,29(10),2145-2147,10.1093/annonc/mdy312,
7. Sunami K, et al.
   Clinical Practice Guidance for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0),Cancer Sci,109(9),2980-2985,10.1111/cas.13730, 2018 Sep
8. Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K.
   An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. Oncogene, 38(9),1398-1409,10.1038/s41388-018-0517-4
9. Ishida M, Kawao N, Okada K, Tatsumi K, Sakai K, Nishio K, Kaji H.
   Serpina3n, dominantly expressed in female osteoblasts, suppresses the phenotypes of differentiated osteoblasts in mice. Endocrinology,159(11), 3775-3790,10.1210/en.2018-00639, 2018 Nov
10. Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.
    Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer Sci,109(12),3921-3933,10.1111/cas.13820, Epub 2018 Nov 13
11. Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P,
    Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. BMC cancer,18(1), 828, 10.1186/s12885-018-4736-4, 2018 Aug
12. Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K.
    Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer. Cancer Sci. 110(1),52-60,10.1111/cas.13860, Epub 2018 Nov 27
13. Iwahashi N, Sakai K, Noguchi T, Yahata T, Toujima S, Nishio K, Ino K.
    A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report,Oncology Letters,16(5), 6431-6436,10.3892/ol.2018.9467, Epub 2018 Sep 20
14. Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K.
    aCGH analysis of predictive biomarkers for response to bevacizumab plus oxaliplatin- or irinotecan-based chemotherapy in patients with metastatic colorectal cancer,The Oncologist,24(3),327-337,10.1634/theoncologist.2018-0119,Epub 2018 Nov 13
15. Hatanaka Y1, de Velasco MA1,2, Oki T1, Shimizu N1, Nozawa M1, Yoshimura K1, Yoshikawa K3, Nishio K2, Uemura H1.
    HOXA10 expression profiling in prostate cancer,The Prostate,79(5),554-563,10.1002/pros.23761,2019
16. Sakai H, Takeda M, Sakai K, Nakamura Y, Ito A, Hayashi H, Tanaka K, Nishio K, Nakagawa K.
    Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. Lung Cancer,127,59-65,10.1016/j.lungcan.2018.11.025,2019 Jan.
17. "Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K.
    Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site,Journal of Clinical Oncology,37(7),570-579,10.1200/JCO.18.00771,2019"
18. Sato T, Takino JI, Nagamine K, Nishio K, Hori T.
    RASGRP2 suppresses apoptosis via inhibition of ROS production in vascular endothelial cells,The Scientific World Journal,vol. 2019,8,10.1155/2019/4639165,
19. Aoyama Y, Sakai K, Kodaka T, Tsunemine H, Nishio K, Itoh T, Inoue D, Takahashi T,
    Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis. Journal of clinical and experimental hematopathology ,59(1),29-33,10.3960/jslrt.18037,Epub 2019 Feb 7
    

臨床研究センター（福岡　和也　教授）

【著書】

1. 福岡和也.
   1から学ぶ医師主導臨床研究の基本. がん研究推進のために知っておきたい最新情報, A・M・S, 東京, 2018.

【論文】

1. 西尾和人、武田真幸、福岡和也、中川和彦、坂井和子.
   がんゲノム医療の進展. 近畿大医誌 (Med J Kindai Univ) 2018; 43: 11-16.